◆ NeutralALMR
AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据,彰显阿尔茨海默病血液生物标志物分析领域的进展
GlobeNewswire Inc.·
Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) 2026 in London. The company introduced its first multiplex blood immunoassay for eMTBR-Tau, a key Alzheimer's biomarker, which can be detected alongside over 220 disease-related proteins in a single workflow. The data demonstrates that combined detection of BD-pTau217 and eMTBR-Tau improves disease stratification compared to single biomarker testing.
Read Full Article at GlobeNewswire Inc. →